HPV Infection and Vaginal Microecology in Immunosuppressed Women
- Sponsor
- Lan Zhu
- Study ID
- NCT06619743
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Anal Cancer
- Cervical Cancer
- HIV Infections
- HPV Infection
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Study Details
This study intends to establish a screening cohort for HPV infection and related tumors in areas with high incidence of HIV infection, explore the screening of cervical cancer and anal cancer and the prognosis management model of precancerous lesions in HIV-infected women, and provide a scientific basis for the formulation of malignant tumor screening policies for this population in my country. In addition, this study intends to characterize the cervical, vaginal, and intestinal microecological characteristics of women with different HIV/HPV infection status, so as to explore the impact of cervical, vaginal, and intestinal microecological characteristics on persistent HPV infection or CIN/cancer progression.
Key Dates
- Start date
- Oct 1, 2024
- Status verified
- Sep 2024
- Primary completion
- Dec 31, 2029
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 10,000 participants (estimated)
Primary Outcome Measure
Detection rate of cervical intraepithelial neoplasia grade 2 or above (CIN2+) in women infected with HIV within 5 years [ Time Frame: 5 years ]
Central Contacts
- Roujie Huang+8618373153750
- Lan Zhu, MD
Related Studies
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruiting · Northwestern University · Chicago, Illinois
- SCOPE: Observational Study of the Consequences of the Protease Inhibitor EraRecruiting · University of California, San Francisco · San Francisco, California
- Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.Recruiting · Syneos Health · Wilmington, North Carolina
- Cervical Cancer Detection Using Optical SpectroscopyRecruiting · Duke University · Durham, North Carolina